1.Bernier, J, Domenge, C, Ozsahin, Met al.Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945–1952.
2.Cooper, J S, Pajak, T F, Forastiere, A Aet al.Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937–1944.
3.Bonner, J A, Harari, P M, Giralt, Jet al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567–578.
4.Adler, J R Jr, Murphy, M J, Chang, S D, Hancock, S L.Image-guided robotic radiosurgery. Neurosurgery 1999; 44: 1299–1306.
5.Chang, S D, Adler, J R. Robotics and radiosurgery – the cyberknife. Stereotact Funct Neurosurg 2001; 76: 204–208.
6.Eisenhauer, E A, Therasse, P, Bogaerts, Jet al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1·1). Eur J Cancer 2009; 45: 228–247.
7.Bachar, G Y, Goh, C, Goldstein, D P, O’Sullivan, B, Irish, J C. Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy. Eur Arch Otorhinolaryngol 2010; 267: 295–301.
8.Argiris, A, Ghebremichael, M, Gilbert, Jet al.Phase III randomized, placebo controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013; 31: 1405–1414.
9.Soulieres, D, Senzer, N N, Vokes, E E, Hidalgo, M, Agarwala, S S, Siu, L L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77–85.
10.Siddiqui, F, Patel, M, Khan, Met al.Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009; 74: 1047–1053.
11.Cacicedo, J, Navarro, A, Alongi, Fet al.The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach. Cancer Treatment Rev 2014; 40: 178–189.
12.Fuks, Z, Kolesnick, R. Engaging the vascular component of the tumor response. Cancer Cell 2005; 8: 89–91.
13.Roh, K W, Jang, J S, Kim, M Set al.Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1348–1355.
14.Le, Q T, Tate, D, Koong, Aet al.Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 1046–1054.
15.Uno, T, Isobe, K, Ueno, Net al.Fractionated stereotactic radiotherapy as a boost treatment for tumors in the head and neck region. J Radiat Res 2010; 51: 449–454.
16.Vargo, J A, Ferris, R L, Clump, D A, Heron, D E. Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer. Front Oncol 2014; 11 (4): 214.